Developing innovative products for molecular imaging of human diseases

At Avid, a wholly owned subsidiary of Eli Lilly and Company (NYSE:LLY), our mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.